Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis

Sonia Villani, Nunzia Zanotta, Federico Ambrogi, Manola Comar, Diego Franciotta, Maria Dolci, Carolina Cason, Rosalia Ticozzi, Pasquale Ferrante, Serena Delbue

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.

Original languageEnglish
Pages (from-to)91-96
Number of pages6
JournalJournal of Neuroimmunology
Volume310
DOIs
Publication statusPublished - Sep 15 2017

Fingerprint

Chemokines
Multiple Sclerosis
Cytokines
Immunity
Interleukin-16
JC Virus
Progressive Multifocal Leukoencephalopathy
Interleukin-7
Serum
Integrins
Interleukin-10
Leukocytes
Urine
Recurrence
Natalizumab
Brain
Therapeutics

Keywords

  • Cytokines
  • JC virus
  • Natalizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Cite this

Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis. / Villani, Sonia; Zanotta, Nunzia; Ambrogi, Federico; Comar, Manola; Franciotta, Diego; Dolci, Maria; Cason, Carolina; Ticozzi, Rosalia; Ferrante, Pasquale; Delbue, Serena.

In: Journal of Neuroimmunology, Vol. 310, 15.09.2017, p. 91-96.

Research output: Contribution to journalArticle

Villani, Sonia ; Zanotta, Nunzia ; Ambrogi, Federico ; Comar, Manola ; Franciotta, Diego ; Dolci, Maria ; Cason, Carolina ; Ticozzi, Rosalia ; Ferrante, Pasquale ; Delbue, Serena. / Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis. In: Journal of Neuroimmunology. 2017 ; Vol. 310. pp. 91-96.
@article{0af70dcd94404219a5956edc615bf1d0,
title = "Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis",
abstract = "Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.",
keywords = "Cytokines, JC virus, Natalizumab",
author = "Sonia Villani and Nunzia Zanotta and Federico Ambrogi and Manola Comar and Diego Franciotta and Maria Dolci and Carolina Cason and Rosalia Ticozzi and Pasquale Ferrante and Serena Delbue",
year = "2017",
month = "9",
day = "15",
doi = "10.1016/j.jneuroim.2017.06.012",
language = "English",
volume = "310",
pages = "91--96",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",

}

TY - JOUR

T1 - Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis

AU - Villani, Sonia

AU - Zanotta, Nunzia

AU - Ambrogi, Federico

AU - Comar, Manola

AU - Franciotta, Diego

AU - Dolci, Maria

AU - Cason, Carolina

AU - Ticozzi, Rosalia

AU - Ferrante, Pasquale

AU - Delbue, Serena

PY - 2017/9/15

Y1 - 2017/9/15

N2 - Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.

AB - Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.

KW - Cytokines

KW - JC virus

KW - Natalizumab

UR - http://www.scopus.com/inward/record.url?scp=85021904700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021904700&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2017.06.012

DO - 10.1016/j.jneuroim.2017.06.012

M3 - Article

C2 - 28778452

AN - SCOPUS:85021904700

VL - 310

SP - 91

EP - 96

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

ER -